|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
Effects of the ABCA1 inducer R3R01 on albuminuria levels in diabetic kidney disease - R3R01-DKD-201
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
An Exploratory Pharmacokinetic Study to Evaluate the Exposure of R3R01 afterAdministration as New Polymorph in Healthy Subjects
100 项与 River 3 Renal Corp. 相关的临床结果
0 项与 River 3 Renal Corp. 相关的专利(医药)
100 项与 River 3 Renal Corp. 相关的药物交易
100 项与 River 3 Renal Corp. 相关的转化医学